Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, Wang H, Hirsch FR, Zhou C.

Transl Lung Cancer Res. 2019 Aug;8(4):352-366. doi: 10.21037/tlcr.2019.08.15.

2.

Galectin-9 in non-small cell lung cancer.

He Y, Jia K, Dziadziuszko R, Zhao S, Zhang X, Deng J, Wang H, Hirsch FR, Zhou C.

Lung Cancer. 2019 Oct;136:80-85. doi: 10.1016/j.lungcan.2019.08.014. Epub 2019 Aug 16.

PMID:
31454748
3.

Authors' Reply.

Camidge DR, Dziadziuszko R; ALEX Investigators.

J Thorac Oncol. 2019 Sep;14(9):e196-e197. doi: 10.1016/j.jtho.2019.05.043. No abstract available.

PMID:
31445734
4.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655-0. doi: 10.1016/j.jtho.2019.07.025. [Epub ahead of print]

PMID:
31398540
5.

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.

Lin CC, Arkenau HT, Lu S, Sachdev J, de Castro Carpeño J, Mita M, Dziadziuszko R, Su WC, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ.

Br J Cancer. 2019 Jul;121(2):131-138. doi: 10.1038/s41416-019-0503-9. Epub 2019 Jun 20.

6.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium.

Lung Cancer. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.

PMID:
31027705
7.

Increased plasma concentration of 4-pyridone-3-carboxamide-1-ß-D-ribonucleoside (4PYR) in lung cancer. Preliminary studies.

Jablonska P, Mierzejewska P, Kutryb-Zajac B, Rzyman W, Dziadziuszko R, Polanska J, Sitkiewicz M, Smolenski RT, Slominska EM.

Nucleosides Nucleotides Nucleic Acids. 2019;38(10):781-787. doi: 10.1080/15257770.2019.1600705. Epub 2019 Apr 16.

PMID:
30990116
8.

Folate/homocysteine metabolism and lung cancer risk among smokers.

Stanisławska-Sachadyn A, Borzyszkowska J, Krzemiński M, Janowicz A, Dziadziuszko R, Jassem J, Rzyman W, Limon J.

PLoS One. 2019 Apr 2;14(4):e0214462. doi: 10.1371/journal.pone.0214462. eCollection 2019.

9.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.

Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.

PMID:
30935574
10.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.

J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20.

11.

Ten years of experience in lung cancer screening in Gdańsk, Poland: a comparative study of the evaluation and surgical treatment of 14 200 participants of 2 lung cancer screening programmes†.

Ostrowski M, Marjański T, Dziedzic R, Jelitto-Górska M, Dziadziuszko K, Szurowska E, Dziadziuszko R, Rzyman W.

Interact Cardiovasc Thorac Surg. 2019 Mar 18. pii: ivz079. doi: 10.1093/icvts/ivz079. [Epub ahead of print]

PMID:
30887048
12.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

Cho BC, Obermannova R, Bearz A, McKeage M, Kim DW, Batra U, Borra G, Orlov S, Kim SW, Geater SL, Postmus PE, Laurie SA, Park K, Yang CT, Ardizzoni A, Bettini AC, de Castro G Jr, Kiertsman F, Chen Z, Lau YY, Viraswami-Appanna K, Passos VQ, Dziadziuszko R.

J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7.

13.

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S.

J Thorac Oncol. 2019 Jun;14(6):1086-1094. doi: 10.1016/j.jtho.2019.02.017. Epub 2019 Feb 27.

PMID:
30825613
14.

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.

Wrona A, Dziadziuszko R, Jassem J.

Cancer Treat Rev. 2018 Dec;71:59-67. doi: 10.1016/j.ctrv.2018.10.011. Epub 2018 Oct 21. Review.

PMID:
30366200
15.

Cardiovascular complications after radiotherapy.

Nabiałek-Trojanowska I, Lewicka E, Wrona A, Kaleta AM, Lewicka-Potocka Z, Raczak G, Dziadziuszko R.

Cardiol J. 2018 Oct 19. doi: 10.5603/CJ.a2018.0120. [Epub ahead of print]

16.

Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice.

Haslett K, De Ruysscher D, Dziadziuszko R, Guckenberger M, Pechoux CL, Nestle U, Slotman B, Faivre-Finn C.

Cancer Treat Res Commun. 2018;17:18-22. doi: 10.1016/j.ctarc.2018.08.004. Epub 2018 Aug 30.

17.

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey.

Lammers A, Mitin T, Moghanaki D, Thomas CR Jr, Timmerman R, Golden SE, Thakurta S, Dziadziuszko R, Slatore CG.

Adv Radiat Oncol. 2018 Jan 31;3(2):125-129. doi: 10.1016/j.adro.2018.01.001. eCollection 2018 Apr-Jun.

18.

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J.

Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121.

19.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.

Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10.

20.

Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.

Szymański FM, Płatek AE, Dziadziuszko R, Łęgosz P, Palczewski P.

Kardiol Pol. 2018;76(3):670. doi: 10.5603/KP.2018.0061. No abstract available.

21.

NSCLC molecular testing in Central and Eastern European countries.

Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, Kovalszky I, Olszewski W, Oz B, Plank L, Timar J.

BMC Cancer. 2018 Mar 9;18(1):269. doi: 10.1186/s12885-018-4023-4.

22.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.

ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. eCollection 2016.

23.

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium.

J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27.

24.

MHC class II expression in lung cancer.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.

Lung Cancer. 2017 Oct;112:75-80. doi: 10.1016/j.lungcan.2017.07.030. Epub 2017 Jul 29.

PMID:
29191604
25.

Serum lipid profile discriminates patients with early lung cancer from healthy controls.

Ros-Mazurczyk M, Jelonek K, Marczyk M, Binczyk F, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Lung Cancer. 2017 Oct;112:69-74. doi: 10.1016/j.lungcan.2017.07.036. Epub 2017 Aug 1.

PMID:
29191603
26.

Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors.

Skrzypski M, Szymanowska-Narloch A, Dziadziuszko R.

Contemp Oncol (Pozn). 2017;21(3):254-258. doi: 10.5114/wo.2017.70116. Epub 2017 Sep 29.

27.

Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.

Ramlau R, Krawczyk P, Dziadziuszko R, Chmielewska I, Milanowski J, Olszewski W, Stencel K, Ramlau-Piątek K, Segiet A, Skroński M, Grudny J, Chorostowska-Wynimko J.

Oncol Lett. 2017 Nov;14(5):5611-5618. doi: 10.3892/ol.2017.6907. Epub 2017 Sep 7.

28.

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.

Roś-Mazurczyk M, Wojakowska A, Marczak Ł, Polański K, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Acta Biochim Pol. 2017;64(3):513-518. doi: 10.18388/abp.2017_1517. Epub 2017 Aug 12.

29.

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators.

N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.

30.

Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment.

Sinacki M, Serkies K, Dziadziuszko R, Narkowicz M, Kamińska J, Lipniewicz J.

J Contemp Brachytherapy. 2017 Feb;9(1):7-13. doi: 10.5114/jcb.2017.66043. Epub 2017 Feb 15.

31.

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, Reck M, Berghmans T, Wasag B, Besse B, Dziadziuszko R.

Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.

32.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.

Med Sci Monit. 2017 Mar 9;23:1208-1216.

33.

LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.

He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR.

J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.

34.

Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer.

Serkies K, Jaśkiewicz J, Dziadziuszko R, Jassem J.

J Contemp Brachytherapy. 2016 Dec;8(6):492-496. doi: 10.5114/jcb.2016.64512. Epub 2016 Dec 9.

35.

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.

Szutowicz-Zielińska E, Konopa K, Kowalczyk A, Suszko-Każarnowicz M, Duchnowska R, Szczęsna A, Ratajska M, Sowa A, Limon J, Biernat W, Burzykowski T, Jassem J, Dziadziuszko R.

Oncotarget. 2017 Mar 7;8(10):17270-17278. doi: 10.18632/oncotarget.13793.

36.

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):110-120. doi: 10.1016/j.jtho.2016.09.002. Epub 2016 Sep 14.

37.

Whole Brain Radiotherapy for Patients with Non-Small Cell Lung Cancer with EGFR Mutations-Why and When?

Dziadziuszko R.

J Thorac Oncol. 2016 Oct;11(10):1604-5. doi: 10.1016/j.jtho.2016.08.121. No abstract available.

38.

Serum mass profile signature as a biomarker of early lung cancer.

Widlak P, Pietrowska M, Polanska J, Marczyk M, Ros-Mazurczyk M, Dziadziuszko R, Jassem J, Rzyman W.

Lung Cancer. 2016 Sep;99:46-52. doi: 10.1016/j.lungcan.2016.06.011. Epub 2016 Jun 16.

PMID:
27565913
39.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, Aisner DL, Doebele RC.

J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.

40.

[Molecular diagnostics of lung cancer].

Ryska A, Dziadziuszko R, Olszewski W, Berzinec P, Öz B, Gottfried M, Cufer T, Samarzija M, Plank L, Ostoros G, Tímár J.

Magy Onkol. 2015 Sep;59(3):259-66. Epub 2015 Aug 18. Review. Hungarian.

41.

Early results of a trimodality treatment for superior sulcus tumors.

Łapiński M, Dziadziuszko R, Sawicka W, Rzyman W.

Kardiochir Torakochirurgia Pol. 2014 Sep;11(3):268-72. doi: 10.5114/kitp.2014.45675. Epub 2014 Sep 28.

42.

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.

Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, Bajcic P, Dusšk L, Zbozinkova Z, Pirker R; INSIGHT study team.

J Thorac Oncol. 2015 Sep;10(9):1370-1374. doi: 10.1097/JTO.0000000000000621.

43.

Stereotactic body radiotherapy for central lung tumours: Author reply.

Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U.

Br J Radiol. 2015 Sep;88(1053):20150532. doi: 10.1259/bjr.20150532. Epub 2015 Jul 7. No abstract available.

44.

Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.

Glubb DM, Paré-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge AS, Mirza O, Zhang W, Seiser EL, Rzyman W, Jassem J, Auman T, Hirsch FR, Owzar K, Camps C, Dziadziuszko R, Innocenti F.

J Thorac Oncol. 2015 Jul;10(7):1067-75. doi: 10.1097/JTO.0000000000000549.

45.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR.

J Thorac Oncol. 2015 Jul;10(7):1083-90. doi: 10.1097/JTO.0000000000000562.

46.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

47.

LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U.

Br J Radiol. 2015 Jul;88(1051):20150036. doi: 10.1259/bjr.20150036. Epub 2015 Apr 15.

48.

CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.

Jarząbek T, Rucińska M, Rogowski W, Lewandowska M, Tujakowski J, Habib M, Kowalczyk A, Byszek A, Dziadziuszko R, Nawrocki S.

Mol Diagn Ther. 2015 Apr;19(2):79-89. doi: 10.1007/s40291-015-0132-9.

49.

Activation of RAS family members confers resistance to ROS1 targeting drugs.

Cargnelutti M, Corso S, Pergolizzi M, Mévellec L, Aisner DL, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S.

Oncotarget. 2015 Mar 10;6(7):5182-94.

50.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O.

J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. Epub 2015 Feb 9.

PMID:
25667280

Supplemental Content

Loading ...
Support Center